retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 💉 Retatrutide may be redefining

P grund av tilltagande psykomotorisk oro och agitation sederades patienten med propofol samt intuberades och vrdades i respirator ver natten

Generics to dramatically cut cost: experts Novo Nordisk the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy had for years held a patent on semaglutide, the active ingredient in those drugs that triggers the release of insulin and is used to treat diabetes and to aid weight loss

They have been shown to have an anti-inflammatory effect - both mechanical as well as biochemical in inhibiting phagocytosis, reducing levels of prostaglandins, interleukin 1, free radicals and cyclic AMP

Glucagonlike peptide1: actions and influence on pancreatic hormone function

doi: 10.1016/j.arth.2023.12.023

18(2): e0281844